Posted by Michael Wonder on 27 Sep 2017
New advance value framework offered as a decision-support tool for reimbursement
25 September 2017 - Researchers at the London School of Economics and Political Science have developed a multiple criteria decision analysis model, The Advance Value Framework, that payers can utilise for evaluating new medicines that come to the market.
The multiple criteria decision analysis (MCDA) framework, the authors explained, allows methodological robustness with different phases and stages for implementation in the context of health technology assessment (HTA).
The new model, they wrote, is a generic value-based model for HTA assessment that can be a decision-making tool for payers. The generic nature is in that it can be used for any type of health technology: medicines, medical devices, and other interventions in health care.
